These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35413121)

  • 1. Horizontal Transmission of Cytomegalovirus in a Rhesus Model Despite High-Level, Vaccine-Elicited Neutralizing Antibody and T-Cell Responses.
    Li J; Wellnitz S; Chi XS; Yue Y; Schmidt KA; Nguyen N; Chen W; Yurgelonis I; Rojas E; Liu Y; Loschko J; Pollozi E; Matsuka YV; Needle E; Vidunas E; Donald RGK; Moran J; Jansen KU; Dormitzer PR; Barry PA; Yang X
    J Infect Dis; 2022 Sep; 226(4):585-594. PubMed ID: 35413121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex.
    Ha S; Li F; Troutman MC; Freed DC; Tang A; Loughney JW; Wang D; Wang IM; Vlasak J; Nickle DC; Rustandi RR; Hamm M; DePhillips PA; Zhang N; McLellan JS; Zhu H; Adler SP; McVoy MA; An Z; Fu TM
    J Virol; 2017 Apr; 91(7):. PubMed ID: 28077654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-existing immunity to cytomegalovirus in macaques influences human CMV vaccine responses in preclinical models.
    Webster H; Valencia S; Kumar A; Chan C; Dennis M; Roark H; Woods A; John S; Carfi A; Permar SR
    Vaccine; 2021 Sep; 39(38):5358-5367. PubMed ID: 34393017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of vaccination with rhesus CMV (RhCMV) soluble gB with a RhCMV replication-defective virus deleted for MHC class I immune evasion genes in a RhCMV challenge model.
    Valencia S; Gill RB; Dowdell KC; Wang Y; Hornung R; Bowman JJ; Lacayo JC; Cohen JI
    Vaccine; 2019 Jan; 37(2):333-342. PubMed ID: 30522906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques.
    Wussow F; Yue Y; Martinez J; Deere JD; Longmate J; Herrmann A; Barry PA; Diamond DJ
    J Virol; 2013 Feb; 87(3):1322-32. PubMed ID: 23152525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of Wild-Type-Like Rhesus Cytomegalovirus Strains following Oral Exposure of Immune-Competent Rhesus Macaques.
    Yue Y; Chang WLW; Li J; Nguyen N; Schmidt KA; Dormitzer PR; Yang X; Barry PA
    J Virol; 2022 Feb; 96(3):e0165321. PubMed ID: 34788083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and protective efficacy of DNA vaccines expressing rhesus cytomegalovirus glycoprotein B, phosphoprotein 65-2, and viral interleukin-10 in rhesus macaques.
    Yue Y; Kaur A; Eberhardt MK; Kassis N; Zhou SS; Tarantal AF; Barry PA
    J Virol; 2007 Feb; 81(3):1095-109. PubMed ID: 17108040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralization of rhesus cytomegalovirus IL-10 reduces horizontal transmission and alters long-term immunity.
    Deere JD; Chang WLW; Villalobos A; Schmidt KA; Deshpande A; Castillo LD; Fike J; Walter MR; Barry PA; Hartigan-O'Connor DJ
    Proc Natl Acad Sci U S A; 2019 Jun; 116(26):13036-13041. PubMed ID: 31189602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody responses to rhesus cytomegalovirus glycoprotein B in naturally infected rhesus macaques.
    Yue Y; Zhou SS; Barry PA
    J Gen Virol; 2003 Dec; 84(Pt 12):3371-3379. PubMed ID: 14645918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques.
    Abel K; Martinez J; Yue Y; Lacey SF; Wang Z; Strelow L; Dasgupta A; Li Z; Schmidt KA; Oxford KL; Assaf B; Longmate JA; Diamond DJ; Barry PA
    J Virol; 2011 Mar; 85(6):2878-90. PubMed ID: 21191005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine-Derived Neutralizing Antibodies to the Human Cytomegalovirus gH/gL Pentamer Potently Block Primary Cytotrophoblast Infection.
    Chiuppesi F; Wussow F; Johnson E; Bian C; Zhuo M; Rajakumar A; Barry PA; Britt WJ; Chakraborty R; Diamond DJ
    J Virol; 2015 Dec; 89(23):11884-98. PubMed ID: 26378171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex.
    Wussow F; Chiuppesi F; Martinez J; Campo J; Johnson E; Flechsig C; Newell M; Tran E; Ortiz J; La Rosa C; Herrmann A; Longmate J; Chakraborty R; Barry PA; Diamond DJ
    PLoS Pathog; 2014 Nov; 10(11):e1004524. PubMed ID: 25412505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization and immunological analysis of the rhesus cytomegalovirus homologue (Rh112) of the human cytomegalovirus UL83 lower matrix phosphoprotein (pp65).
    Yue Y; Kaur A; Zhou SS; Barry PA
    J Gen Virol; 2006 Apr; 87(Pt 4):777-787. PubMed ID: 16528025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.
    Nelson CS; Jenks JA; Pardi N; Goodwin M; Roark H; Edwards W; McLellan JS; Pollara J; Weissman D; Permar SR
    J Virol; 2020 Apr; 94(9):. PubMed ID: 32051265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells.
    McVoy MA; Lee R; Saccoccio FM; Hartikka J; Smith LR; Mahajan R; Wang JB; Cui X; Adler SP
    Vaccine; 2015 Dec; 33(51):7328-7336. PubMed ID: 26597035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and Functional Characterization of a Novel Fc Gamma-Binding Glycoprotein in Rhesus Cytomegalovirus.
    Kolb P; Sijmons S; McArdle MR; Taher H; Womack J; Hughes C; Ventura A; Jarvis MA; Stahl-Hennig C; Hansen S; Picker LJ; Malouli D; Hengel H; Früh K
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30487278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limited dissemination and shedding of the UL128 complex-intact, UL/b'-defective rhesus cytomegalovirus strain 180.92.
    Assaf BT; Mansfield KG; Strelow L; Westmoreland SV; Barry PA; Kaur A
    J Virol; 2014 Aug; 88(16):9310-20. PubMed ID: 24899204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.
    Schleiss MR; Berka U; Watson E; Aistleithner M; Kiefmann B; Mangeat B; Swanson EC; Gillis PA; Hernandez-Alvarado N; Fernández-Alarcón C; Zabeli JC; Pinschewer DD; Lilja AE; Schwendinger M; Guirakhoo F; Monath TP; Orlinger KK
    Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27795301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Host immune responses to a viral immune modulating protein: immunogenicity of viral interleukin-10 in rhesus cytomegalovirus-infected rhesus macaques.
    Eberhardt MK; Chang WL; Logsdon NJ; Yue Y; Walter MR; Barry PA
    PLoS One; 2012; 7(5):e37931. PubMed ID: 22655082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploitation of Interleukin-10 (IL-10) Signaling Pathways: Alternate Roles of Viral and Cellular IL-10 in Rhesus Cytomegalovirus Infection.
    Eberhardt MK; Deshpande A; Fike J; Short R; Schmidt KA; Blozis SA; Walter MR; Barry PA
    J Virol; 2016 Nov; 90(21):9920-9930. PubMed ID: 27558431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.